Background: Adrenal insufficiency secondary to long-term systemic glucocorticoid treatment is a well-recognized problem. However, the extent and prevalence of this phenomenon has not been thoroughly explored. Objectives: To investigate the prevalence of adrenal insufficiency in patients with polymyalgia reumatica (PMR) and giant cell arteritis (GCA) during treatment with low doses of prednisolone (<10mg/day) assessed by the adrenal response to a 250 microgram Synachten ® test. To explore whether potential adrenal insuffiency was associated with duration of steroid treatment. Methods: Outpatients were examined when prednisolone doses were between 2.5 and 10 mg/day for >6 months. Adrenal function was evaluated after a 48-hour pause of prednisolone, using a 250 μg Synachten ® (ACTH) test where plasma cortisol levels were measured at baseline and 30 minutes after Synacthen injection. Adrenal insufficiency was defined as plasma cortisol <420 nmol/l after 30 minutes according to the validated Roche Elecsys ® Cortisol II assay. Accummulated doses of prednisolone for the individual patients were calculated. A multiple regression analysis was used to test for an association between the plasma cortisol after 30 minutes and the accumulated dose of prednisolone. Results: Forty-eight patients (35 women) completed the Synachten ® test. Seven (14.6%) patients exhibited adrenal insufficiency. Median age was 74 years (Range: 57-89 years). Median accumulated dose was 3.402 mg (Range: 820-21.200mg). Median plasma cortisol after 30 minutes was 562 nmol/l (Range: 92-989 nmol/l). In patients with adrenal insufficiency, median plasma cortisol was 122 nmol/l (Range: 56-275 nmol/l) at baseline and 207 (Range: 92-420 nmol/l) after 30 minutes. In patients without adrenal insufficiency, median plasma cortisol was 359 (Range: 9-710 nmol/l) at baseline and 584 nmol/l (Range: 429-989 nmol/l) after 30 minutes. Accumulated doses of prednisolone did not differ in patients with and without adrenal insufficiency (p=0.49). Plasma cortisol after 30 minutes was not associated with accumulated dose of prednisolone (estimate −0.01, 95% CI: −0.02 to 5.39, p=0.06), when adjusting for sex and age. Conclusions: Iatrogenic adrenal insufficiency was prevalent among patients with PMR or GCA treated with low dose prednisolone. Adrenal function was not associated with the accumulated dose of prednisolone, or the duration of steroid treatment. A Synacthen ® test is a valuable tool to evaluate the adrenal function, when steroid treatment is tapered in these patients. Latent symptoms of adrenal insufficiency may explain why some patients are reluctant to discontinue steroid treatment even after the inflammatory condition has gone into remission. Rheumatology and Clinical Immunology, University Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany Background: The cytokine Flt3 ligand is an important cofactor for early hematopoiesis by mainly driving the development of lymphoid and early B-cell precursors. In the periphery functions of Flt3 are more pleiotropic involving the differentiation of regulatory T-cells, dendritic cells as well as peripheral B-cells. Besides its well-known roles in hematological disorders and as an indicator of bone marrow (BM) output capacity, the possible involvement of FLT3 ligand in autoimmune disorders was only discovered recently. Objectives: Our primary aim was to analyze if FLT3 ligand serum concentrations are affected in AAV patients. Secondary aims were to correlate the FLT3 ligand serum concentrations with clinical and laboratory parameters. And, since FLT3 ligand concentrations are elevated in different states of bone marrow failure, we also wanted to evaluate FLT 3ligand as a marker for treatment related BM toxicity in AAV patients. Methods: We performed a cross sectional study using a sandwich ELISA to determine FLT3 ligand concentrations in the serum of 98 well characterized AAV patients (69 GPA, 20 MPA and 9 EGPA) and 144 healthy controls (HC). Statistical evaluation was done using Mann-Whitney or unpaired, two-tailed Student's t-test. Results: In patients with AAV, FLT3 ligand concentrations were significantly elevated (207 pg/ml +/-116.2 in AAV versus 142.5 pg/ml +/-65.98 in HC; p<0.0001). Disease specific analysis revealed significantly elevated FLT3 ligand concentrations in GPA (217.6 pg/ml +/-123; p<0.0001), but no significant differences for MPA and EGPA when compared to HC. FLT3 ligand concentrations did not correlate to serological or clinical markers of disease activity, however, overall disease activity was low in the studied cohort. To assess the influences of treatment regimen on FLT3 ligand concentrations, we focused our analysis on treatment histories of cyclophosphamide (CYC) and azathioprine (AZA) and grouped the patient cohort according to the cumulative CYC dose (< or >5g)
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Conclusions:
Flt3 ligand concentrations are elevated in patients with AAV, especially in patients with GPA. The elevation more likely reflects the therapeutic regimen and history than disease activity as we could show that patients with more intensive treatment including both CYC and AZA show higher FLT3 ligand serum levels when compared to patients with less intense therapy. 
